{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:44:05Z","timestamp":1790001845307,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010571","name":"BMBF Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ161L0214B"],"award-info":[{"award-number":["FKZ161L0214B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["390857198"],"award-info":[{"award-number":["390857198"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ161L0214C ClinspectM"],"award-info":[{"award-number":["FKZ161L0214C ClinspectM"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ161L0214C"],"award-info":[{"award-number":["FKZ161L0214C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ebiom.2023.104456","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T05:15:48Z","timestamp":1675487748000},"page":"104456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-5062","authenticated-orcid":false,"given":"Alexander M.","family":"Bernhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Tiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teupser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dichgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer-Hendrik","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endy","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"N\u00fcbling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesca","family":"Holdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"H\u00f6nikl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Giesbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Breimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan F.","family":"Lichtenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Imhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-6784","authenticated-orcid":false,"given":"Bernhard","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2023.104456_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib4","first-page":"1","article-title":"Method of the year 2012","volume":"10","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.ebiom.2023.104456_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","article-title":"Multiplatform approach for plasma proteomics: complementarity of olink proximity extension assay technology to mass spectrometry-based protein profiling","volume":"20","author":"Petrera","year":"2021","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.ebiom.2023.104456_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2023.104456_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for alzheimer disease-related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.ebiom.2023.104456_bib9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30828","article-title":"Precision oncology based on omics data: the NCT Heidelberg experience","volume":"141","author":"Horak","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2023.104456_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ebiom.2023.104456_bib12","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.32358","article-title":"Variant classification in precision oncology","volume":"145","author":"Leichsenring","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2023.104456_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Pepe","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ebiom.2023.104456_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"Amur","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104456_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.2554","article-title":"Biomarker qualification at the European medicines agency: a review of biomarker qualification procedures from 2008 to 2020","volume":"112","author":"Bakker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2023.104456_bib17","series-title":"BEST (biomarkers, EndpointS, and other tools) resource","year":"2016"},{"key":"10.1016\/j.ebiom.2023.104456_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1559-0275-10-13","article-title":"Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges","volume":"10","author":"F\u00fcz\u00e9ry","year":"2013","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.ebiom.2023.104456_bib19","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-07-4535","article-title":"Validation of analytical methods for biomarkers employed in drug development","volume":"14","author":"Chau","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2023.104456_bib20","first-page":"213","article-title":"Bioanalytical method validation and its pharmaceutical application - a review","volume":"5","author":"V Sonawane","year":"2014","journal-title":"J\u00a0Pharm Anal"},{"key":"10.1016\/j.ebiom.2023.104456_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1198\/sbr.2011.09026","article-title":"Regulatory issues in use of biomarkers in oncology trials","volume":"3","author":"Chakravarty","year":"2011","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.ebiom.2023.104456_bib22","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/s41467-020-19957-6","article-title":"Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies","volume":"11","author":"Mattsson-Carlgren","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104456_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd2174","article-title":"A\u00a0cost-effectiveness approach to the qualification and acceptance of biomarkers","volume":"5","author":"Williams","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2023.104456_bib24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11060-020-03467-y","article-title":"High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients","volume":"147","author":"H\u00f6nikl","year":"2020","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib26","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/0008-5472.CAN-03-1254","article-title":"Molecular classification and survival prediction in human gliomas based on proteome analysis","volume":"64","author":"Iwadate","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2023.104456_bib27","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/nm.2994","article-title":"Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy","volume":"18","author":"Shao","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104456_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.15350","article-title":"Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies","volume":"158","author":"Schmid","year":"2021","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.ebiom.2023.104456_bib29","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.28949","article-title":"Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma","volume":"120","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ebiom.2023.104456_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/noq170","article-title":"Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor","volume":"13","author":"Crocker","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1055-9965.EPI-09-1077","article-title":"Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis","volume":"19","author":"Sreekanthreddy","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ebiom.2023.104456_bib32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/neuonc\/nor117","article-title":"Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14740\/wjon1228","article-title":"Serum neurofilament light, glial fibrillary acidic protein and tau are possible serum biomarkers for activity of brain metastases and gliomas","volume":"10","author":"Hepner","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib34","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ebiom.2023.104456_bib35","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/srep07140","article-title":"Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers","volume":"4","author":"Sharma","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2023.104456_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-018-0459-7","article-title":"Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis","volume":"11","author":"Parnetti","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.ebiom.2023.104456_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib38","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104456_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib40","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD Clinical Diagnostic Criteria","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.ebiom.2023.104456_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2023.104456_bib42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.ebiom.2023.104456_bib43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2023.104456_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","article-title":"4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration","volume":"139","author":"Saijo","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ebiom.2023.104456_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ebiom.2023.104456_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib47","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1038\/s41598-018-21788-x","article-title":"Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease","volume":"8","author":"Byrne","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2023.104456_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.ebiom.2023.104456_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ebiom.2023.104456_bib51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ebiom.2023.104456_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104456_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104456_bib54","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"A\u00a0biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2023.104456_bib55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","article-title":"CSF \u03b1-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders","volume":"20","author":"Mondello","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ebiom.2023.104456_bib56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","article-title":"CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls","volume":"20","author":"Herbert","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ebiom.2023.104456_bib57","first-page":"12","article-title":"Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients","volume":"87","author":"Steinacker","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ebiom.2023.104456_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.24980","article-title":"Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis","volume":"82","author":"Gendron","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib59","first-page":"2129","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib60","series-title":"Research C for DE and Aducanumab (marketed as aduhelm) information","year":"2021"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104456_bib61","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2023.104456_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.ebiom.2023.104456_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102834","article-title":"Decreased salivary lactoferrin levels are specific to Alzheimer's disease","volume":"57","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2023.104456_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41582-020-0350-6","article-title":"Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke","volume":"16","author":"Montaner","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(09)70266-2","article-title":"Medical complications after stroke","volume":"9","author":"Kumar","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib67","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archneur.62.7.1130","article-title":"Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction","volume":"62","author":"Foerch","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib68","doi-asserted-by":"crossref","first-page":"e1338","DOI":"10.1212\/WNL.0000000000006282","article-title":"Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke","volume":"91","author":"Tiedt","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2023.104456_bib69","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ebiom.2023.104456_bib70","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000004257","article-title":"Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke","volume":"89","author":"Zhong","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2023.104456_bib71","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/0960327117751236","article-title":"Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke","volume":"37","author":"Liu","year":"2018","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.ebiom.2023.104456_bib72","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1468-1331.2004.00822.x","article-title":"CSF isoelectrofocusing in a large cohort of MS and other neurological diseases","volume":"11","author":"Bourahoui","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib73","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/135245850100700603","article-title":"Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS","volume":"7","author":"Tintor\u00e9","year":"2001","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2023.104456_bib74","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","article-title":"Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report","volume":"57","author":"Andersson","year":"1994","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ebiom.2023.104456_bib75","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","article-title":"The utility of cerebrospinal fluid analysis in patients with multiple sclerosis","volume":"9","author":"Stangel","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS","volume":"115","author":"Villar","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ebiom.2023.104456_bib77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.10441","article-title":"Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis","volume":"53","author":"Villar","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib78","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.ebiom.2023.104456_bib79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ebiom.2023.104456_bib80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.ebiom.2023.104456_bib82","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib83","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2023.104456_bib84","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/1352458515624558","article-title":"Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone","volume":"22","author":"\u00d6hrfelt","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2023.104456_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011986","article-title":"The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)","volume":"5","author":"Brettschneider","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2023.104456_bib86","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2023.104456_bib87","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib89","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2023.104456_bib90","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","article-title":"Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis","volume":"9","author":"Polman","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6578","key":"10.1016\/j.ebiom.2023.104456_bib91","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2023.104456_bib92","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2023.104456_bib93","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib94","article-title":"Clinical spectrum of tauopathies","volume":"13","author":"Olfati","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib95","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ebiom.2023.104456_bib96","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/jamaneurol.2013.3961","article-title":"TDP-43 pathology, cognitive decline, and dementia in old age","volume":"70","author":"Wilson","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebiom.2023.104456_bib97","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","article-title":"Impact of multiple pathologies on the threshold for clinically overt dementia","volume":"134","author":"Kapasi","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ebiom.2023.104456_bib98","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104456_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease","volume":"7","author":"Bj\u00f6rkqvist","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2023.104456_bib100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3233\/JAD-130380","article-title":"Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study","volume":"38","author":"Kiddle","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ebiom.2023.104456_bib101","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/505612a","article-title":"Policy: NIH plans to enhance reproducibility","volume":"505","author":"Collins","year":"2014","journal-title":"Nature"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642300021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642300021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:35:34Z","timestamp":1778873734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642300021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":101,"alternative-id":["S235239642300021X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104456","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104456"}}